Regulators are asking harder questions about data integrity. Audit trails must be complete. Provenance must be defensible. Inspection readiness is no longer a project — it's a permanent state. Most data systems were designed for collection. Few were designed for the standard regulators now apply.
For decades, data integrity in life sciences has been treated as a documentation discipline — SOPs, validation reports and manual audit trails wrapped around systems built primarily for collection, not for proving what happened. That model is breaking under the weight of modern regulatory scrutiny.
FDA, EMA, MHRA and equivalent bodies have all hardened their data integrity expectations. Inspectors no longer accept reconstructed evidence assembled under pressure — they expect a complete, continuous record that was correct from the point of capture. Organisations whose infrastructure cannot produce that record face delayed approvals, failed audits and lost commercial opportunities.
The BioChain provides the underlying data-integrity architecture that supports every stage of the life-sciences lifecycle — without requiring you to replace the systems you already run.
A shared platform means sharing infrastructure with organisations you may be competing with, or submitting to regulators alongside. A Private BioChain gives your organisation a dedicated environment — deployed within your own infrastructure or a private cloud — so the provenance and integrity benefits above apply to your data alone, integrated with the LIMS, ELN and quality systems you already run.
Public health, agritech, food safety, environmental research — if your work depends on biological data integrity, we should talk.